EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
Source: EQS
"Over the past decade, diagnostics with Gallium-68-based drugs have experienced a huge growth, which we were able to actively influence with our GalliaPharm®," explained Dr. Radionuclide generators offer a cost-effective alternative for the radiolabeling of biomolecules, which can be used in positron emission tomography (PET) or other applications. To date, radiolabeled products have mainly been a cancer diagnostic tool, with Gallium-68-based PET diagnostics being used primarily for tumors of the prostate or neuroendocrine system. For other diseases, radioisotopes such as fluorine-18 are mostly used to radiolabel biomolecules. This requires millions to be invested in cyclotrons. The Ge-68/Ga-68 generator, on the other hand, has a compact size and can be purchased much more affordably. This reduces costs in nuclear medicine clinics and practices and increases flexibility. Contact
|
Language: | English |
Company: | Eckert & Ziegler SE |
Robert-Rössle-Str.10 | |
13125 |
|
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in |
EQS News ID: | 1961253 |
End of News |
|
1961253 05.08.2024 CET/CEST